Innovation
Tylon’s philosophy is to conduct its operations in a manner that is ethical, proactive, environmentally conscious and sensitive to all its stakeholders. We operate in compliance with all regulatory and policy requirements and there are regular audits to ensure that controls and compliances are maintained at a high standard.
Tylon’s commitment towards environmental and social responsibility has existed since its inception; however, a structured approach was adopted in 2022 by establishing management systems. This accelerated our efforts and enhanced the focus on environmental and social aspects by solemnising the environmental policy and creating dedicated institutional positions for the purpose.
With changing global and regional challenges and emerging best practices in the pharmaceutical sector we have updated and upgraded our policies and practices at regular intervals. Our recent amendment to the EHS policy includes the commitment to ensure resource efficiency and conservation, to address climate change by reducing carbon emission intensity, and to adopt technologies and practices that minimise environmental impacts and prevent pollution. The potential future effects of global climate change are recognized and our efforts are focused on this cause.
Our Research Philosophy
Science is at the heart of Tylon. Our scientists work closely with doctors, patients and the business development teams to generate innovative concepts and ideas to harness both, market needs and synergies across therapeutic areas. Whether it is specialty, generics, difficult to make technology intensive products, Active Pharmaceutical Ingredients (APIs) or Novel Drug Delivery Systems (NDDS), our scientists have the capability to deliver high quality products to fulfil the unmet need in the marketplace. We have more than 2000 scientists working in six research centers across India, Israel and USA who have a passion for innovation and longing to provide better healthcare to humanity at large.
Technology
Our capabilities span the development of differentiated products including liposomal delivery, inhalers, lyophilised injections, nasal sprays besides developing controlled and modified release dosage forms. We are also pioneers in delivery systems of ophthalmology, cardiology, peptides, CNS and oncology.
Our knowledge in pharmaceutical research allows a rapid ramp-up of a diverse range of immediate and Novel Delivery Systems spanning oral, parenteral, topical and inhalation dosage forms. Our formulation expertise lies in the areas of taste masking, spray-drying, drug-layering, nano-milling among others. The ability to develop difficult-to-make, complex APIs by using latest technologies is the key differentiating factor of our research.
Strong Intellectual Property
Our research strategy and implementation are well supported by a strong intellectual property team having expertise and experience in chemistry, analytical techniques, dosage forms and global patent law. Sun files numerous patents every year to protect its intellectual property in markets of interest. We have close to 1400 patents to our credit.
Our R&D centres have been audited and approved by international regulatory authorities, including the US FDA and European authorities. The R&D centers at Vadodara, & Gurgaon in India are certified by the National GLP Compliance Monitoring Authority.